Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume and stock price turning positive!
I believe IMTX will be on the agenda for discussion here next week:
https://www.bryangarnier.com/bryan-garnier-innovation-series-tcr-therapeutics/
Stay well bro.
Nice new presentation on the website...
PPS not to understand here...great chances for new investors...
Solid support on the BID
At the moment at least, these things can change in a heartbeat though.
Another article:
https://www.evaluate.com/vantage/articles/news/trial-results/prame-looks-real-deal
TCRX targetting Mage and Prame
TCRX presentation here:
https://ir.tscan.com/static-files/e37317c4-d6a7-48c3-9071-c11d7cfd222c
see page 14 of 43 info on CD8 effect - VERY POSITIVE FOR IMTX, imo.
What i found interesting about the interim data that was recently released was the Phase 1b cohort had 80% confirmed objective response. That was the IMA203 alone with the 4 and 5 dose level escalation. Allbeit a low sample - only 5 patients, however interesting data.
Given the early data of IMA203 alone (80% objective response for dose level 4 and 5) The IMA203 +CD8 (t-cell helper) and/or IMA203 plus Opdivo (checkpoint inhibitor - BMS) has serious potential to be a breakout therapy, imo.
The data for IMA 203 CD8 and Opdivo should be out soon, if not December i would say 1st quarter of 2023, imo.
(IMTX and TCRX = 2 top notch biotechs in TCR-T, imo.)
Thank u! In the near future I think we' ll see a strong development here. I have the feeling we fly under the radar for the moment. But once we get started...we have a strong pipeline here..."only" one success and we talk about 100plus in my opinion...
FY 2022 earnings estimate update:
https://www.marketbeat.com/instant-alerts/nasdaq-imtx-analyst-earnings-estimates-2022-11-2-3/
"Immatics (NASDAQ:IMTX - Get Rating) - Analysts at Chardan Capital boosted their FY2022 earnings estimates for Immatics in a report issued on Monday, November 21st. Chardan Capital analyst Y. Livshits now expects that the company will earn $0.81 per share for the year, up from their prior forecast of $0.23. Chardan Capital has a "Buy" rating and a $28.00 price target on the stock. The consensus estimate for Immatics' current full-year earnings is $0.44 per share. Chardan Capital also issued estimates for Immatics' FY2023 earnings at ($1.31) EPS. "
Interesting info here regarding a Phase 2 trial over at PDS Biotech:
https://ih.advfn.com/stock-market/NASDAQ/pds-biotechnology-PDSB/stock-news/89544084/pds-biotech-announces-100-clinical-response-in-ce
Excerpt 1
"As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8+ T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8+ T cells are important mediators of antigen-specific immunity."
Remember IMTX held back the results from the IMA203 +CD8 part of the trial. Might be interesting results - also Opdivo + IMA 203 results ( BMS) held back.
IMTX trials sre still in an early phase, imo. TCR-T category still early as well, imo.
Not sure if IMTX will be presenting at the ASH. TScan is and is also in the TCR-T category with a very strategic approach, imo.
https://www.hematology.org/meetings/annual-meeting
IMTX Top 5 Institutional Holders:
OWNER NAME / DATE / SHARES HELD
BAKER BROS. ADVISORS LP 09/30/2022 4,423,731
NANTAHALA CAPITAL MANAGEMENT, LLC 09/30/2022 2,713,968
PERCEPTIVE ADVISORS LLC 09/30/2022 2,500,000
FEDERATED HERMES, INC. 09/30/2022 2,106,000
WELLINGTON MANAGEMENT GROUP LLP 09/30/2022 1,878,660
TCR Bispecifics Programs
TCER® IMA401 (MAGEA4/8) – IMA401 is being developed in collaboration with Bristol Myers Squibb; 9 centers in Germany have been activated and are enrolling patients.
Interesting website here on History of BMS / click on "competitors" for further data:
https://www.zippia.com/bristol-myers-squibb-careers-1752/history/
On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration. Initially announced on February 20, 2020, the terms of the agreement included a €45 Million (~$50 Million) upfront payment to Immatics and the potential for additional milestone and royalty payments in return for access to two of Immatics’ TCR-T programs. As communicated to Immatics, GSK’s decision was made unrelated to the programs and the progress achieved in the collaboration to date. The termination will be effective on December 26, 2022.
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89581771/immatics-announces-third-quarter-2022-financial-r
If you go back to this article here (Oct.25/22), had they included Immatics in the article it would have been more definitively clear that GSK was exiting the TCR-T space, imo. Most likely it didn't fit with their business model.
https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/
Article is not a free article, link here / intro:
https://www.science.org/doi/10.1126/scitranslmed.abo6135#core-collateral-purchase-access
COL-ing out TCR-Ts
Adoptive T cell therapy targeting neoantigens is a promising new therapeutic technique; however, the lack of shared neoantigens across patients limits the use of this technique. To overcome this, Kim et al. identified a shared pan-cancer collagen type VI a-3 (COL6A3) epitope that was presented on tumor stroma and was the result of an alternative splicing event. They created affinity-enhanced T cell receptor T (TCR-T) cells and treated mice in vivo to show regression in tumors that expressed physiological levels of the targeted pHLA without toxicity to normal cells. This method represents a promising treatment to target multiple cancer types and warrants further clinical investigation.
Abstract
T cell receptor (TCR)–based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide–human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI a-3 (COL6A3) gene that is highly presented on tumor stroma across multiple solid cancers due to a tumor-specific alternative splicing event that rarely occurs outside the tumor microenvironment. T cells expressing natural COL6A3-specific TCRs demonstrated only modest activity against cells presenting high copy numbers of COL6A3 pHLAs. One of these TCRs was affinity-enhanced, enabling transduced T cells to specifically eliminate tumors in vivo that expressed similar copy numbers of pHLAs as primary tumor specimens. The enhanced TCR variants exhibited a favorable safety profile with no detectable off-target reactivity, paving the way to initiate clinical trials using COL6A3-specific TCRs to target an array of solid tumors.
From the 3rd quarter 10Q:
IND = Investigational New Drug
ACTengine® IMA204 (COL6A3 exon 6) – Immatics and the University of Pennsylvania co-authored a research paper published in the peer-reviewed journal, Science Translational Medicine, that highlighted Immatics’ differentiated approach to develop TCR-based therapies through its proprietary discovery platforms, XPRESIDENT® and XCEPTOR®. With this approach, Immatics identified a novel proprietary HLA-A*02:01-presented target generated by a tumor-specific alternative splicing event in the abundantly expressed protein collagen type VI alpha-3 (COL6A3). This target is expressed at high target density across multiple solid cancer indications and specific to the tumor stroma. Targeting tumor stroma provides an innovative therapeutic opportunity to disrupt the tumor microenvironment. Immatics has engineered target-specific, affinity-enhanced proprietary TCRs, one of them being CD8-independent and thus facilitating targeting of COL6A3 exon 6 positive cells by both CD4 and CD8 T cells. The TCR-T candidate, IMA204 was able to eliminate tumor cells at physiological target levels in in vitro studies and in vivo mouse models. Due to Immatics focusing its clinical resources on the three IMA203 Phase 1b cohorts as well as accelerating the clinical development for the PRAME TCER® IMA402, the company has delayed the IND submission for an ACTengine® candidate directed against COL6A3 exon 6.
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89581771/immatics-announces-third-quarter-2022-financial-r
But it seems to be a strategic decision from GSK and has a least nothing to do with Immatics. Reading the news I feel confident Immatics will have success in the future and these levels of pps are history in the near future...At this stage the company is already much more worth....half of the marketcap do they in cash....
It is Opdivo. From memory, the first patient was dosed back in May.
Thanks it's here in black and white:
https://ca.finance.yahoo.com/news/immatics-announces-third-quarter-2022-120000183.html
Cohort B – The first patient in the Phase 1b expansion cohort B was treated with IMA203 in combination with the PD-1 immune checkpoint inhibitor nivolumab in May 2022. Patients will be treated at RP2D.
Nivolumab / Opdivo = Bristol Myers Squibb
https://www.opdivo.com/
That better explains the recent 100 million + capital raise.
Revenue from GSK all dried up.
Confirmed here as well.
https://www.biospace.com/article/gsk-continues-to-thin-cell-therapy-pipeline-as-it-ends-partnership-with-immatics/
Do we know which checkpoint inhibitor IMTX was working with, with the IMA203 + checkpoint inhibitor trial?
Oh, that could make sense. I think that's possible. But in this case this could explode next year. I see here a good chance for a tenbagger and more...the marketcap for now is nothing regarding to the potential in the future...
I concur with that analysis.
What i find interesting is that they reported interim clinical data on IMA203 on October 10/22
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257173/immatics-reports-interim-clinical-data-update-on-a
but held back the data on IMA203 + checkpoint inhibitor and IMA203CD8 - pushing the release of that data into 2023:
"we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8. As we continue to shift our focus from Phase 1a to Phase 1b, we look forward to reporting meaningful data throughout 2023, "
Then the capital raise at $10.09 on the same day Oct.10/22
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257170/immatics-announces-110-million-underwritten-offer
Is it just my imagination, or could the sequence of events ( IMA203 limited clinical data Oct.10/22 - capital raise Oct.10/22 - GSK cutting ties with Lyell and Adaptimmune Oct.25/22) indicate that some positive to very positive news is afoot (IMA203 checkpt. , IMA203CD8) with IMTX?
GSK maybe taking a bigger position before the wildly amazing news is released in 2023 - just speculating a little, because imo, the stock is acting as though big buyers are accumulating.
Oh, thank you!
That is interesting! For my opinion the pps has to be much higher, already at this stage. But Biotech often needs only a view days to make 100% and more. Once this starts we will never see that niveau again...
Interesting development here with GSK
https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/
Excerpt from article:
"GSK did not respond to BioPharma Dive’s request for comment. The company has another cell therapy deal with German biotech Immatics Biotechnologies that’s focused on solid tumors."
The previous presentation coupled with, the recent capital raise, and now this info are all positive indicators for IMTX, imo.
Looks very promising and professional!
New Corporate presentation October 18/22
https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6
Looks excellent imo.
Both news are great in my eyes! I believe it could be the starting point of a longer nice development here....
IMTX Capital Raise:
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257170/immatics-announces-110-million-underwritten-offer
Some big dollars and big institutional involvement here with IMTX.
I hope so,... and turning back to accumulation with an uptick in stock price looks positive.
Nice to see double digits again, however the short position is still on the rise by +/- 280,000 shares as of 09/15/22 in comparison to the amount reported on 08/31/22
https://www.nasdaq.com/market-activity/stocks/imtx/short-interest
Slightly bearish signal, imo, however sophisticated hedge funds can sometimes utilize short positions with options in their investment strategies, so i have heard, so the short position may not be too much of a concern.
Looks a little like consolidation is over....
Tracking Baker Bros. portfolio - IMTX
https://seekingalpha.com/article/4543704-baker-brothers-portfolio-q2-2022-update
IMTX Pipeline for review:
https://immatics.com/our-pipeline/
Just doing some review of 1Q/22 report here:
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/88273266/immatics-announces-first-quarter-2022-financial-re
Here is what caught my attention:
"The next data read-out for the IMA203 monotherapy cohort is planned for 2H 2022."
Hope the results are better than the IMA202 program which was terminated.
The dive on the chart sort of says results could be poor,however it has dropped on lighterish volume. We are well into 2H of 2022.
Of INTEREST:
New holder of 1,127, 970 shares as of June 30/22 = Rock Springs Capital Management LLP
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
Fourth on this list:
https://www.nasdaq.com/market-activity/institutional-portfolio/rock-springs-capital-management-lp-927624
Not much info on Rock Springs publicly available:
https://www.rockspringscapital.com/
https://pitchbook.com/profiles/advisor/57226-51#overview
However, i believe attracting a venture capital fund like Rock Springs is positive for IMTX.
Not looking good here - IMTX
Hope this is just a trading anomaly.
Thank u!
Sooner or later it will go much higher! Consolidation will be over soon. Nice chance to buy some more...
Geulah Livshits maintains her "strong buy" rating on Immatics.
https://www.wallstreetzen.com/stocks/us/nasdaq/imtx/stock-forecast
Click on analyst name to see their track record/details.
Yes, I think so, too. I saw the same development at BNTX about two years ago. There was a fund that made always cash...but at some point IT stopped...
And yes, the biosector is known die high volatility...perhaps today or tomorrow we‘ll see a big climb...
I've ruled out a "capital raise",imo, as they had over 300 million USD at June 30/22.
Institutional adjustments is a possibility, and it appeared that the sell off today was a continuation of the selloff that started last Friday afternoon.
Notice that Baker Bros. is still the #1 Institution holding, that is always a positive, imo.
https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings
Short attack is always possible as well, Citadel was reported here at Marketbeat as shorting.
Scroll down to the bottom under Frequently Asked Questions for comments about Citadel.
https://www.marketbeat.com/stocks/NASDAQ/IMTX/short-interest/
Nasdaq short interest to August 31/22 still rising
https://www.nasdaq.com/market-activity/stocks/imtx/short-interest
Overall, these moves are all to common in biotech, impossible to predict, imo, and in this instance holding long term is the best strategy, imo, given the level of conviction i have in this company.
Today not really to understand, but good chance for new investors...
Thank you! I have read it.I totally agree. It all looks very promising in my eyes. We are in an early stage, but this could easily be a multi-bagger with some time....
It's nice exposure at ESMO 2022 there is no doubt about that.
Details on IMA402 have been published before in their June 22 Corporate update presentation here:
https://investors.immatics.com/static-files/3b9b921d-f109-447a-89cd-ab73db220caa
Starting at page 40 is where they discuss IMA402
IMA401 is targetting Mage and is in collaboration with BMS (checkpoint inhibitor - likely a CAR-T) - starting at page 37.
Not sure where clinical trials are at with IMA401.
Overall, imo, there is evidence appearing that TCR-T will be superior to CAR-T both in efficacy and reduced side effects/toxicities. Both are huge advances in medicine and potential game changers, imo
Multiple reasons here for IMTX to continue the uptrend.
That are great news....Green week coming...
Interesting news on a Saturday - ESMO 2022 related
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89032003/immatics-presents-comprehensive-preclinical-data-s
ESMO Presentation
https://oncologypro.esmo.org/meeting-resources/esmo-congress/targeting-solid-tumors-with-ima402-a-next-generation-bispecific-t-cell-engaging-receptor-against-prame
Background
T cell engaging bispecifics redirecting T cells towards human leukocyte antigen (HLA)-presented peptides are emerging as promising treatment modality for patients with solid tumors. We have developed bispecific T cell engaging receptor (TCER®) molecules, which consist of an affinity maturated TCR, a humanized T cell-recruiting antibody and an Fc-part conferring half-life extension and favorable stability characteristics. Our TCER® candidate IMA402 targets an HLA-A*02-presented peptide derived from PRAME, which is highly prevalent across multiple solid tumors incl. melanoma, gynecological cancers, lung cancer, sarcoma and others.
Methods
After systematic evaluation, a TCR with high avidity and specificity towards the PRAME target peptide was selected for affinity maturation via yeast surface display resulting in more than 1,000-fold increased binding affinity while retaining specificity. The maturated TCR was then incorporated into our TCER® format.
Results
IMA402 showed in vitro anti-tumor activity at picomolar concentrations against tumor cells with naturally occurring PRAME target peptide levels and demonstrated absence of reactivity towards normal tissue cells at relevant concentration, suggesting a broad therapeutic window. In preclinical xenograft mouse models, IMA402 led to consistent tumor regression including complete remissions and showed a serum half-life of several days. In these models, low affinity T cell recruiting domain demonstrated superior tumor control compared to analogous TCER® molecules with widely used higher-affinity T cell recruiters. Distinct affinities of the TCR (high) and T cell recruiter (low) are designed to optimize biodistribution and activation of T cells at the tumor site, aiming to reduce occurrence of immune-related toxicities like cytokine release syndrome, while achieving relevant doses in tumor tissue.
Conclusions
Upon preclinical proof-of-concept for the novel bispecific T cell engager IMA402 GMP manufacturing was initiated and is currently ongoing. IMA402 directed against PRAME will be the second TCER® entering clinical development with start of the phase 1 basket trial in several solid tumor indications planned for 2023.
Not sure what caused the sell off on Friday., but that happens, actually with any stock from time to time.
Just wondering at the same time though, if maybe there was an expectation that the IND for IMA402 was expected a bit earlier then the stated Q2 / 2023.
If the studies end positive and they develop something against cancer, we will see totally other pps....in that case I see some 100's in the future...
And yes, big names are in board...GLTY
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
195
|
Created
|
07/06/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |